(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

SOM BIOTECH

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

SOM BIOTECH

ST13

US500000079355609

Classe

5, 42

Pedido

79355609

Registro

7404026

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

43

Atualização mais recente

07/12/2024

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5, 42

Data de depósito

20/07/2022

Data de registro

04/06/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

04/06/2024

Última transação

04/06/2024

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

5

Tipo de titular

85

Localização do titular

ES

Examinador

HARMON, RAYMOND

Localização atual

FILE REPOSITORY (FRANCONIA)

Descrição da marca

The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size.

Titulares e representantes

Titulares

SOM INNOVATION BIOTECH, S.A.

Representantes

Justin R. Young DTL Ltd.

Classificação técnica

Classes Nice

Classe 5Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer

Classe 42

Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research

Publicações

Histórico de despachos e eventos da marca no USPTO.

43 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

07/12/2024

FICS

FINAL DISPOSITION NOTICE SENT TO IB

16/11/2024

FIMP

FINAL DISPOSITION PROCESSED

15/11/2024

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

04/09/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

04/06/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

04/06/2024

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

07/05/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

17/04/2024

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

17/04/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

19/03/2024

PUBO

PUBLISHED FOR OPPOSITION

19/03/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

28/02/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

28/02/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

14/02/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

14/02/2024

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

14/02/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

14/02/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

14/02/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

14/02/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

14/02/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

14/02/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/02/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/02/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/02/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

10/01/2024

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

10/01/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

10/01/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

10/01/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

10/01/2024

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

10/01/2024

RFNT

REFUSAL PROCESSED BY IB

28/08/2023

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

05/08/2023

RFRR

REFUSAL PROCESSED BY MPU

05/08/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

30/06/2023

CNRT

NON-FINAL ACTION WRITTEN

29/06/2023

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

26/06/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

17/05/2023

CNRT

NON-FINAL ACTION WRITTEN

16/05/2023

DOCK

ASSIGNED TO EXAMINER

05/05/2023

MAFR

APPLICATION FILING RECEIPT MAILED

02/12/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

28/11/2022

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

25/11/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

17/11/2022

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace SOM BIOTECH ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.